Article Text

Download PDFPDF
Anti-TNF-associated immunogenicity: use a retroactive drug but a proactive approach

Statistics from


  • Twitter @

  • Contributors AS, PDC and DRVL: manuscript preparation and review. All of the authors approved the submitted manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests AS has received educational support from Pfizer. PDC has served as a consultant, an advisory board member or a speaker for AbbVie, Baxter, Ferring, Janssen, Shire and Takeda, and received research support from Ferring, Shire, Janssen, AbbVie and Takeda. DRVL has received educational grants or research support from Pfizer, Takeda, Ferring, Shire and has received consultancy and/or speaker’s fees from Pfizer, Janssen, Abbvie, Ferring, Vifor and Emerge Health.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.